SCHEMBL24009092

SCHEMBL24009092

COc1ccc2c(Oc3ccc(S(C)(=N)=O)cc3)ncnc2c1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 8/20 0.56
TRPA1 O75762 1/20 0.53
AURKB Q96GD4 1/20 0.47
PDGFRB P09619 2/20 0.47
FLT4 P35916 2/20 0.47
FLT3 P36888 2/20 0.47
KDR P35968 7/20 0.46
PDGFRA P16234 1/20 0.46
RET P07949 1/20 0.42
KIF5B P33176 1/20 0.42
EGFR P00533 1/20 0.41
RAF1 P04049 2/20 0.41
BRAF P15056 2/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24010524 0.86 KDR (0.60) CSF1RTRPA1AURKBPDGFRBFLT4
SCHEMBL20782521 0.86 CSF1R (0.57) CSF1RTRPA1AURKBPDGFRBFLT4
SCHEMBL24009212 0.80 MET (0.51) CSF1RAURKBPDGFRBKDRPDGFRA
SCHEMBL24837325 0.80 MET (0.51) CSF1RAURKBPDGFRBKDRPDGFRA
SCHEMBL24837431 0.80 MET (0.51) CSF1RAURKBPDGFRBKDRPDGFRA
SCHEMBL24009054 0.79 CSF1R (0.50) CSF1RTRPA1PDGFRBFLT4FLT3
SCHEMBL20782442 0.79 CSF1R (0.64) CSF1RTRPA1AURKBPDGFRBFLT4
SCHEMBL24010243 0.78 PTGS1 (0.44) RAF1LMNA
SCHEMBL24008907 0.77 POLB (0.44) CSF1RPDGFRBFLT4FLT3KDR
SCHEMBL13763602 0.76 TRPA1 (0.62) CSF1RTRPA1AURKBPDGFRBFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-01-05 US disclosed
WO-2021225969-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 CSF1R 3458/4885TRPA1 4878/4885AURKB 2437/4885
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 ENPP1, ENPP3, SMPD1 CSF1R 3458/4885TRPA1 4878/4885AURKB 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.